BackClarus Therapeutics Holdings Overview
Clarus Therapeutics Holdings Inc

Clarus Therapeutics Holdings Return on Equity

Clarus Therapeutics Holdings (CRXT) has a ROE of 4.49%, above the sector sector average of -4.03%.

Get informed when a big investor buys or sells

+ Follow

ROE

448.76%

Return on Equity

448.76%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

Average ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Clarus Therapeutics Holdings (CRXT) FAQ

The latest ROE for CRXT is 4.49%. That is above the sector sector average of -4.03%. Investors often review this figure alongside Clarus Therapeutics Holdings's historical trend and sector peers before judging valuation or financial health.

Against its sector companies, CRXT currently prints 4.49% for ROE, while the sector average sits near -4.03%. That is roughly 11249.4% above the sector mean. Large gaps often invite a closer look at Clarus Therapeutics Holdings's growth, margins, and balance sheet.

Return on Equity shows how effectively Clarus Therapeutics Holdings converts resources into returns. At 4.49%, CRXT may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting CRXT's ROE (4.49%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.